Head-to-head evidence
MK0653A, ezetimibe (+) simvastatin vs Rosuvamibe
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: HMG-CoA reductase / NPC1L1 · full Atherosclerotic Cardiovascular Disease pipeline
MK0653A, ezetimibe (+) simvastatin
Developed by Organon
NCT00092651 · Phase 3 · completed
The study was randomized and double-blind, included active comparator groups, and enrolled 1,398 participants. Its primary endpoint was the surrogate measure of change in plasma LDL-C after 12 weeks, but results and statistical significance were not posted, so the endpoint cannot be judged as met or missed.
Rosuvamibe
Developed by Yuhan Corporation
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MK0653A, ezetimibe (+) simvastatin's landscape · Rosuvamibe's landscape